ArticleEuropean journal of medical research2026
Contralateral C7 nerve transfer combined with human acellular nerve allograft as a viable strategy for spastic upper limb paralysis.
Article in European journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPeripheral nerve surgery is a potential treatment for chronic spastic hemiplegia, but the role of contralateral C7 nerve transfer combined with human acellular nerve allograft remains to be explored. This study aimed to investigate the functional outcomes of contralateral C7 nerve transfer combined with human acellular nerve allograft for spastic upper limb paralysis.
methodsFrom January 2020 to December 2023, 53 patients with unilateral spastic upper limb paralysis completed a 12-month follow-up. 17 patients underwent contralateral C7 nerve transfer combined with human acellular nerve allografts, while 36 received rehabilitation alone. The primary outcome was the change in the Fugl-Meyer Assessment. Safety outcomes included adverse events and changes in muscle strength and motor-sensory function assessment of the arm and hand on the side of the donor C7 nerve.
resultsThe overall Fugl-Meyer Assessment increased by 15.88 ± 3.54 in the surgery group and 2.36 ± 2.34 in the rehabilitation group (difference, 13.52, P < 0.001). Spasticity improvements were observed on the Modified Ashworth Scale for various muscle groups (P < 0.001). Adverse events related to the donor nerve included mild numbness in the radial three digits, slightly weakened triceps brachii strength, and tolerable peripheral neuropathic pain. No other adverse event relative to the bilateral brachial nerve occurred except for the C7 nerve section, and all events resolved within 3 months for all patients.
conclusionOur study suggests that the combination of the contralateral C7 nerve transfer and the human acellular nerve allograft may be a viable treatment option for individuals experiencing long-term spastic upper limb impairment following chronic cerebral hemisphere injury.
trial registrationThis clinical study was registered with the Chinese Clinical Trial Registry, and the registration number is ChiCTR2500099694.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.